Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.42 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.42 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.42 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20240364 | 0.98 | GSR (0.61) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL344574 | 0.98 | GSR (0.61) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL1404247 | 0.98 | GSR (0.61) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Hydrochloric Acid SCHEMBL3825519 | 0.96 | GSR (0.59) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Hydrochloric Acid SCHEMBL2099474 | 0.96 | GSR (0.59) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL29075853 | 0.96 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL1537223 | 0.96 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| SCHEMBL997560 | 0.96 | GSR (0.52) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Hydrochloric Acid SCHEMBL11287494 | 0.94 | GSR (0.57) | GSRGNAI3GNAO1GNAI1RNPEP | |
| Hydrochloric Acid SCHEMBL11287492 | 0.94 | GSR (0.57) | GSRGNAI3GNAO1GNAI1RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117925458-A | Bacillus BJ-1 for degrading lignin and preparation method of bacillus BJ-1 microbial inoculum thereof | 中国科学院东北地理与农业生态研究所 | 2024-04-26 | — | — | CN | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | COHBAR, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023173174-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2023-09-21 | — | — | WO | disclosed |
| US-11753445-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230218710-A1 | METHOD OF TREATING CORONAVIRUS INFECTIONS | COHBAR, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230137562-A1 | TAU AGGREGATION INHIBITORS | ADRX, INC. | 2023-05-04 | — | — | US | disclosed |
| EP-4168009-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | Hangzhou DAC Biotech Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| EP-4135738-A2 | METHOD OF TREATING CORONAVIRUS INFECTIONS | Cohbar Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-1807118-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007060409-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007056362-A2 | GLUCAGON ANALOGS EXHIBITING PHYSIOLOGICAL SOLUBILITY AND STABILITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070077201-A1 | Stem cell expansion and uses | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | BIOVIE INC. | 2007-01-18 | — | — | US | disclosed |
| WO-2006129859-A2 | COMBINATIONS OF A SQUALENE SYNTHASE INHIBITOR AND A HMG-COA REDUCTASE INHIBITOR FOR TREATING HYPERLIPIDEMIA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006110172-A2 | STEROID ANALOGS AND CHARACTERIZATION AND TREATMENT METHODS | HOLLIS-EDEN PHARMACEUTICALS.INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1650201-A1 | BENZOXAZEPINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-04-26 | — | — | EP | disclosed |
| WO-2004076425-A1 | IMPROVED SYNTHESIS OF MACROCYCLIC TETRAAMIDO COMPOUNDS AND NEW METAL INSERTION PROCESS | CARNEGIE MELLON UNIVERSITY (US) | 2004-09-10 | — | — | WO | disclosed |
| US-3960658-A | RAPID IDENTIFICATION OF UROPATHOGENIC BACTERIA | CENTAUR CHEMICAL CO. (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372434-A1 | METHOD OF TREATING FIBROSIS WITH A COMBINATION THERAPY | MMP1, MMP8, COL2A1 | GSR 635/4885GNAI3 4153/4885GNAO1 4386/4885 |
| US-20070014719-A1 | Steroid analogs and characterization and treatment methods | CYP17A1, HSD17B11, HSD3B1 | GSR 1076/4885GNAI3 1921/4885GNAO1 2107/4885 |
| US-20070077201-A1 | Stem cell expansion and uses | NES, CD44, FGF2 | GSR 2775/4885GNAI3 2584/4885GNAO1 3822/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | GSR 4259/4885GNAI3 969/4885GNAO1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.